Background: Vitamin D deficit is known as a changeable risk factor in many common cancers, but its impact on Hodgkin lymphoma (HL) is not well-studied. Methods: This study assessed pre-treatment vit. D levels in HL individuals who received prospective treatment. It included 35 individuals from the North Bihar Population. Results: Vitamin D levels < 30 nmol/L were observed in 49% of patients before therapy. Vitamin D deficiency increased relapse/refractory rates. Relapsed/refractory patients exhibited lower median baseline Vitamin D levels (21.4 nmol/L) than non-relapsed (35.5). The non-relapsed group had 41% Vitamin D insufficiency, while relapsed/refractory patients had 68%. The 10-year progression-free survival of vitamin D-deficient patients was 17.6% poorer with a hazard ratio of 2.13. Their 10-year survival rate was 11.1% lower and their hazard ratio was 1.82. These results were consistent across studies and treatments. Vitamin D status independently predicted prognosis, suggesting it may impact HL chemotherapeutic sensitivity. Conclusion: It is advised that future randomized clinical trials include vitamin D assessment and replacement in order to ascertain the function of vitamin D replacement treatment in HL, based on these medical and preclinical findings.

Background: Vitamin D deficit is known as a changeable risk factor in many common cancers, but its impact on Hodgkin lymphoma (HL) is not well-studied. Methods: This study assessed pre-treatment vit. D levels in HL individuals who received prospective treatment. It included 35 individuals from the North Bihar Population. Results: Vitamin D levels < 30 nmol/L were observed in 49% of patients before therapy. Vitamin D deficiency increased relapse/refractory rates. Relapsed/refractory patients exhibited lower median baseline Vitamin D levels (21.4 nmol/L) than non-relapsed (35.5). The non-relapsed group had 41% Vitamin D insufficiency, while relapsed/refractory patients had 68%. The 10-year progression-free survival of vitamin D-deficient patients was 17.6% poorer with a hazard ratio of 2.13. Their 10-year survival rate was 11.1% lower and their hazard ratio was 1.82. These results were consistent across studies and treatments. Vitamin D status independently predicted prognosis, suggesting it may impact HL chemotherapeutic sensitivity. Conclusion: It is advised that future randomized clinical trials include vitamin D assessment and replacement in order to ascertain the function of vitamin D replacement treatment in HL, based on these medical and preclinical findings.